Join us on Thursday, June 17 at 12 p.m. ET for ‘A groundbreaking first step in ALS treatment,’ to learn about a collaboration between the Weizmann Institute of Science and the Montreal Neurological Institute-Hospital (The Neuro at McGill) on a new approach to treat Amyotrophic Lateral Sclerosis (ALS). 

We will be joined by Weizmann’s Prof. Eran Hornstein and The Neuro’s Dr. Angela Genge, who are conducting a trial to examine the safety, tolerability and target engagement of Enoxacin in patients with ALS.  

People with ALS have decreased microRNA levels in their motor neurons and Enoxacin was previously shown in Prof. Hornstein’s lab to increase these levels in cell and animal models. This new trial is a first step in what could be an innovative avenue for the treatment of ALS. 

It is thanks to Apotex that these clinical trials are moving forward. We are so very grateful. Read more.  

Your support is appreciated and we hope you will join us.